[Genetic Risk Factors of Macrovascular Complications in Patients With Type 2 Diabetes]. 2017

A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
I.P. Pavlov St.-Petersburg State Medical University, St.-Petersburg, Russia.

High risk of macrovascular complications in patients with type 2 diabetes mellitus (T2DM) is caused by insulin resistance and atherogenic dyslipidemia that may be genetically determined. The aim of this study was to assess the association of polymorphic genetic variants APOA5 (S19W/rs3135506), CETP (Taq1B/rs708272), PON1 (Q192R /rs662) and PPARG (Pro12Ala /rs1801282) with T2DM and macrovascular complications in patients with T2DM resident in Northwestern Russia. We examined 386 patients with T2DM and 199 healthy controls. Genotyping was performed by polymerase chain reaction followed by restriction analysis. The study revealed the protective role of allele 12Ala of PPARG gene against T2DM development (odds ratio [OR]=0.58; 95% confidence interval [CI] 0.39-0.85). B1B1 genotype of CETP was associated with increased risk of stroke in T2DM patients (OR=1.85; 95%CI1.07-3.21). RR genotype of PON1 was associated with increased risk of T2DM with stroke (OR=2.98; 95%CI1.01-8.84). According to study results Pro12Ala (rs1801282) variant of PPARG affected the risk of T2DM; polymorphic variants of CETP (Taq1B/rs708272) and PON1 (Q192R/rs662) contributed to the risk of macrovascular complications of T2DM.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D003925 Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS. Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012426 Russia A country located in north Asia bordering the Arctic Ocean, extending from Europe (the portion west of the Urals) to the North Pacific Ocean. The capital is Moscow. Russian S.F.S.R.,Russian Federation (Europe),Russian SFSR
D043303 Aryldialkylphosphatase An enzyme which catalyzes the hydrolysis of an aryl-dialkyl phosphate to form dialkyl phosphate and an aryl alcohol. It can hydrolyze a broad spectrum of organophosphate substrates and a number of aromatic carboxylic acid esters. It may also mediate an enzymatic protection of LOW DENSITY LIPOPROTEINS against oxidative modification and the consequent series of events leading to ATHEROMA formation. The enzyme was previously regarded to be identical with Arylesterase (EC 3.1.1.2). Aryl-dialkyl Phosphatase,Arylalkylphosphatase,Homocysteine Thiolactone Hydrolase,OPA Anhydrase,OPH Enzyme,Organophosphorus Acid Anhydrase,Organophosphorus Acid Anhydrolase,Organophosphorus Acid Hydrolase,Organophosphorus Hydrolase,Paraoxonase,Paraoxonase-1,Paraoxonase-2,Acid Anhydrase, Organophosphorus,Acid Anhydrolase, Organophosphorus,Acid Hydrolase, Organophosphorus,Anhydrase, OPA,Anhydrase, Organophosphorus Acid,Anhydrolase, Organophosphorus Acid,Aryl dialkyl Phosphatase,Enzyme, OPH,Hydrolase, Homocysteine Thiolactone,Hydrolase, Organophosphorus,Hydrolase, Organophosphorus Acid,Paraoxonase 1,Paraoxonase 2,Phosphatase, Aryl-dialkyl,Thiolactone Hydrolase, Homocysteine
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic

Related Publications

A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
September 2001, Best practice & research. Clinical endocrinology & metabolism,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
June 1999, Scandinavian journal of primary health care,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
March 2008, Vnitrni lekarstvi,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
January 2020, Current vascular pharmacology,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
June 2014, The Journal of the Association of Physicians of India,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
January 2016, Indian journal of endocrinology and metabolism,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
August 2021, World journal of diabetes,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
January 2017, International journal of endocrinology,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
August 2009, Pediatrics international : official journal of the Japan Pediatric Society,
A A Bystrova, and A S Ulitina, and M V Kim, and S A Skoryukova, and V V Miroshnikova, and A A Panteleeva, and N A Korelskaya, and Zhu He Zhu He, and M A Nikolaev, and S N Pchelina, and E I Baranova, and E I Krasilnikova
January 2011, Cerebrovascular diseases (Basel, Switzerland),
Copied contents to your clipboard!